{"id":"W3130435961","doi":"10.1158/1538-7445.sabcs20-ps10-05","title":"Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Letrozole; Clinical endpoint; Internal medicine; Discontinuation; Breast cancer; Adverse effect; Population; Goserelin; Metastatic breast cancer; Phases of clinical research; Oncology; Cancer; Clinical trial; Gastroenterology; Surgery; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006122468,0.0005139977,0.001413839,0.0006196365,0.0004954206,0.00004901873,0.0004991338,0.00018703,0.00552473],"category_scores_gemma":[0.0002231252,0.0003829387,0.0003872331,0.004224875,0.0009614087,0.0004770316,0.0002643202,0.001291074,0.0000075287],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002685028,"about_ca_system_score_gemma":0.001192375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003468128,"about_ca_topic_score_gemma":0.002585548,"domain_scores_codex":[0.9938971,0.0007106331,0.001045925,0.001079041,0.002120149,0.001147139],"domain_scores_gemma":[0.9952194,0.0004514916,0.0005394824,0.0008998191,0.002525658,0.0003641412],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4001861,0.006580491,0.2311693,0.0003891888,0.01010404,0.00006181087,0.006893412,0.000888191,0.242341,0.0001904795,0.001247374,0.09994856],"study_design_scores_gemma":[0.1262741,0.001278945,0.8098493,0.0006421217,0.0004114651,0.00000204972,0.001442557,0.00002256813,0.05877414,0.00004931524,0.0007599919,0.0004934181],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888598,0.0009163095,0.00004934604,0.001935004,0.0002456361,0.002483251,0.005184378,0.00004200049,0.0002842931],"genre_scores_gemma":[0.9969822,0.0004718335,0.0002010247,0.0001988349,0.0002991608,0.000714837,0.000649173,0.00009781945,0.0003851722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.57868,"threshold_uncertainty_score":0.9998623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04300735938034665,"score_gpt":0.3947596595600426,"score_spread":0.3517523001796959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}